Brief Summary
This study aims to assess a new cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs drug, GRWD5769, in patients with advancedat a late stage, far along cancer.
Intervention/Treatment
- Drug: GRWD5769.
Inclusion Criteria
Module 1A, 1B & 1C
- Participant has cytologically or histologically confirmed locally advanced or metastatic solid malignancy for which no further standard of care (SoC) therapy is available (or no SoC therapy exists), or who have been offered and declined SoC therapy, or are intolerant of SoC therapy.
- Participant has measurable disease per RECIST 1.1/iRECIST.
Module 1B specific
- Participant has at least one tumoura tissue mass that forms from groups of unhealthy cells lesion amenable to serial biopsies and is willing to provide consent for biopsies and has measurable disease per RECIST 1.1/iRECIST, excluding the lesion(s) identified for biopsyremoval of a section of tissue to analyse for cancer cells.
Module 1D specific
Additional selection criteria for Module 1 Part D will be described in a future protocol amendment.